Allstate Corp Purchases 5,492 Shares of Illumina, Inc. $ILMN

Allstate Corp lifted its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 96.7% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 11,170 shares of the life sciences company’s stock after acquiring an additional 5,492 shares during the quarter. Allstate Corp’s holdings in Illumina were worth $1,465,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in ILMN. Capital World Investors grew its stake in Illumina by 20.0% during the third quarter. Capital World Investors now owns 19,976,850 shares of the life sciences company’s stock valued at $1,897,178,000 after acquiring an additional 3,331,542 shares in the last quarter. Nordea Investment Management AB boosted its position in shares of Illumina by 2,792.2% during the 4th quarter. Nordea Investment Management AB now owns 944,500 shares of the life sciences company’s stock valued at $124,145,000 after acquiring an additional 911,843 shares during the last quarter. Massachusetts Financial Services Co. MA bought a new stake in shares of Illumina during the 4th quarter valued at about $73,532,000. State Street Corp boosted its position in shares of Illumina by 6.8% during the 3rd quarter. State Street Corp now owns 5,999,790 shares of the life sciences company’s stock valued at $569,800,000 after acquiring an additional 382,520 shares during the last quarter. Finally, Duquesne Family Office LLC purchased a new position in shares of Illumina during the 2nd quarter valued at about $28,682,000. Institutional investors own 89.42% of the company’s stock.

Insider Buying and Selling at Illumina

In other news, Director Keith A. Meister sold 104,393 shares of the stock in a transaction on Thursday, May 14th. The shares were sold at an average price of $145.34, for a total value of $15,172,478.62. Following the sale, the director owned 3,500,048 shares of the company’s stock, valued at approximately $508,696,976.32. This represents a 2.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Christensen Jakob Wedel sold 700 shares of the stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $139.04, for a total transaction of $97,328.00. Following the completion of the sale, the senior vice president directly owned 15,056 shares in the company, valued at approximately $2,093,386.24. This represents a 4.44% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 330,160 shares of company stock worth $48,028,308. Insiders own 2.90% of the company’s stock.

Analyst Ratings Changes

ILMN has been the subject of several recent research reports. UBS Group reiterated a “neutral” rating and issued a $135.00 price objective on shares of Illumina in a research report on Friday, February 6th. Citigroup boosted their target price on shares of Illumina from $80.00 to $95.00 and gave the company a “sell” rating in a report on Monday, May 4th. Daiwa Securities Group raised Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 target price on the stock in a research note on Thursday, May 14th. Barclays increased their target price on Illumina from $110.00 to $122.00 and gave the stock an “underweight” rating in a research note on Friday, May 1st. Finally, JPMorgan Chase & Co. increased their price objective on Illumina from $120.00 to $125.00 and gave the company a “neutral” rating in a research report on Friday, May 1st. Seven equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Illumina presently has an average rating of “Hold” and an average target price of $137.75.

Illumina Stock Performance

NASDAQ:ILMN opened at $162.96 on Friday. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.75 and a quick ratio of 1.36. Illumina, Inc. has a 1 year low of $78.79 and a 1 year high of $165.37. The stock’s 50 day simple moving average is $133.73 and its two-hundred day simple moving average is $132.02. The company has a market cap of $24.66 billion, a price-to-earnings ratio of 29.63, a PEG ratio of 2.63 and a beta of 1.42.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.05 by $0.10. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The business had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.07 billion. During the same quarter in the previous year, the company posted $0.97 EPS. The company’s revenue was up 4.8% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, equities analysts anticipate that Illumina, Inc. will post 5.2 earnings per share for the current fiscal year.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.